MONTREAL, July 26 /PRNewswire-FirstCall/ -- Celmed BioSciences Inc., a private biopharmaceutical company active in the field of oncology, today announces four key appointments to its Board of Directors. Mr. Pierre Marc Johnson, already a director of the company, will assume the responsibilities of Chairman of the Board.
Mr. Johnson, lawyer and physician, former Premier of Quebec, has been of counsel to Heenan Blaikie since 1996. He is recognized for his expertise in international trade, negotiations and international partnerships as well as environmental and health law. He is advisor to the Commission for Environmental Cooperation (CEC), an international organization created by Canada, Mexico and the United States under the North-American Agreement of Environmental Cooperation (NAAEC), and has chaired its Ten-year Review and assessment committee. He has extensive experience in international negotiations with the United Nations on environmental and development issues, and is chief negotiator for the Quebec Government on the softwood lumber Canada/USA negotiation. Mr. Johnson sits on public and private Boards and advisory groups in North America and Europe.
Ms. Monique Lefebvre, Ph.D., joins Celmed's Board. She is also a director of Transcontinental G.T.C. Ltd., ART Advanced Research Technologies Inc. and Desjardins Financial Security. She also sits on the Boards of Trustees of the Canada Foundation for Innovation, the Centre d'acces a l'Information Juridique du Barreau du Quebec and the National Circus School. Ms. Lefebvre has served as President for various organizations, such as the Computer Research Institute of Montreal and the Montreal Transition Committee, as well as Chairman of Innovatech du Grand Montreal and Director of Cognicase. She has also held key positions in large companies, namely President of Quebecor Multimedia Inc. and Vice President, Quebec and Atlantic Canada at Ericcson Canada Inc.
Mr. Roger L. Headrick, formerly Chairman of the Board of NewBiotics Inc. recently acquired by Celmed, brings more than 30 years of executive management experience in finance and strategic planning. He also is the managing general partner of HMCH Ventures, a private venture capital investment partnership and serves as President and CEO of Protatek International Inc., a biotechnology process-engineering company. He serves on the Boards of Directors for Caremark Rx Inc. and Crompton Corporation. Previously, he was deputy controller of Exxon Corp., executive vice president and CFO of The Pillsbury Company, and co- owner, president and CEO of the Minnesota Vikings. He has served on the Board of Directors for Canji Inc. and is a member of the University of Minnesota Cancer Center advisory board, the board of trustees of the Minnesota Medical Foundation and The Burnham Institute, San Diego.
Martijn Kleijwegt, managing partner of Life Sciences Partners B.V. (LSP), has gained extensive experience in the life sciences sector as general partner of Euroventures Benelux, a (euro)90 million pan-European venture capital fund based in the Netherlands. Mr Kleijwegt decided to focus on human life sciences within the Euroventures organization as early as 1988. He served on the supervisory Board of, amongst others, Rhein Biotech (G, NL), Qiagen (G) and Quadrant (UK). In 1998, Mr Kleijwegt co-founded the first Life Sciences Partners fund, followed by the second fund in December 2000. Through a large number of investments in the life science sector, he has gained extensive experience in all aspects of biotech venture capital. On behalf of LSP, he served on the supervisory board of Crucell (NL) and NewBiotics (USA) and currently serves on the supervisory boards of Ness (IS). He holds a masters degree in economics from Amsterdam University, and speaks Dutch, English, French and German.
Finally, Mr. Martial Lacroix, Ph.D., is vice president of GeneChem Therapeutics Ventures Fund LP. Prior to this, Dr. Lacroix was a co-founder of BioChem Pharma Inc. and acted as director of technology transfer. From 1986 to 1995, he held a number of positions with BioChem ImmunoSystems, Inc., including director of research and development and director of quality control. Between 1981 and 1986, Dr. Lacroix was a professor-scientist in the Department of Virology at Institut Armand-Frappier. Dr. Lacroix received Bachelors and Masters degrees in biochemistry from University of Montreal and a Ph.D. from the University of Toronto. Dr. Lacroix has authored 33 scientific publications and holds 8 issued patents.
The five other members are Andre de Villers, M.D., President and Chief Executive Officer, Celmed BioSciences Inc., Thierry Abribat, Ph.D., D.V.M., Executive Vice President, Business Development, Theratechnologies Inc., Gerald Andre, Eng., Ph.D., Vice President, Corporate Development, Theratechnologies Inc., Gaetan Gravel, Portfolio Manager, Life Sciences, Solidarity Fund QFL, Martin Saint-Jean, Development Manager, SGF Sante.
About Celmed BioSciences
Celmed BioSciences Inc., is a private Canadian biopharmaceutical company active in the field of oncology. The Company has a portfolio of products at various stages of development targeting several different cancers and related immune disorders. Its two lead products, TH9402 from the Theralux(TM) platform, and NB1011, from the ECTA platform, are in or nearing Phase I/II clinical development. Theralux(TM) is currently being evaluated in such conditions as acute and chronic graft-versus-host disease (GvHD) and non- Hodgkin's lymphoma (NHL), while NB1011 is preparing for a Phase I/II study in cancers exhibiting high levels of an enzyme called thymidylate synthase (TS). More information about Celmed can be found at http://www.celmedbio.com/ .
This press release contains forward-looking statements, which reflect
Celmed's current expectations regarding future development of its
products and technologies. Such statements inherently involve numerous
risks and uncertainties, including the availability of funds and
resources to pursue preclinical and clinical projects, the successful and
timely completion of clinical studies, and the granting of the necessary
authorizations by the regulatory authorities. Actual future results may
differ materially from the anticipated results expressed in the forward
looking statements contained in this press release.
CELMED BIOSCIENCES INC.